Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome

Dianne M. Heijink; Elisabeth G. E. de Vries; Jan J. Koornstra; Geke A. P. Hospers; Robert M. W. Hofstra; Marcel A. T. M. van Vugt; Steven de Jong; Jan H. Kleibeuker

doi:10.1016/j.critrevonc.2010.11.009

Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome

Dianne M. Heijink, Elisabeth G. E. de Vries, Jan J. Koornstra, Geke A. P. Hospers, Robert M. W. Hofstra, Marcel A. T. M. van Vugt, Steven de Jong, Jan H. Kleibeuker^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

Lynch syndrome (LS) is caused by a germline mutation in one of the mismatch repair (MMR) genes. The resulting loss of MMR gene function induces a strong mutator phenotype and predisposition to colorectal cancer (CRC). LS mutation carriers undergo regular colonoscopic surveillance and have extensive colonic resection in case of cancer because of the chance of metachronous tumors. Given the high risk and early onset of CRC, LS mutation carriers are good candidates for chemoprevention. Furthermore, evidence increases indicating that the response of MMR-deficient tumors to standard chemotherapy and radiotherapy differs from that of MMR-proficient tumors. Efforts should thus be directed at designing tailored strategies concerning both chemoprevention and medical cancer treatment for LS individuals. This review provides guidance for future studies in this field based on results from clinical and preclinical research. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Original language	English
Pages (from-to)	264-277
Number of pages	14
Journal	Critical Reviews in Oncology/Hematology
Volume	80
Issue number	2
DOIs	https://doi.org/10.1016/j.critrevonc.2010.11.009
Publication status	Published - Nov-2011

Keywords

Lynch syndrome
Mismatch repair
Microsatellite instability
Chemoprevention
Cancer treatment
DNA MISMATCH-REPAIR
III COLON-CANCER
ACTIVATED PROTEIN-KINASE
MICROSATELLITE-INSTABILITY
CELL-LINES
ADJUVANT CHEMOTHERAPY
IONIZING-RADIATION
DEFICIENT CELLS
RANDOMIZED-TRIAL
INSTITUTE WORKSHOP

Access to Document

10.1016/j.critrevonc.2010.11.009

Handle.net

Persistent link

Cite this

@article{44a2a8dfe1df407abb7456b1ffe7ce91,

title = "Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome",

abstract = "Lynch syndrome (LS) is caused by a germline mutation in one of the mismatch repair (MMR) genes. The resulting loss of MMR gene function induces a strong mutator phenotype and predisposition to colorectal cancer (CRC). LS mutation carriers undergo regular colonoscopic surveillance and have extensive colonic resection in case of cancer because of the chance of metachronous tumors. Given the high risk and early onset of CRC, LS mutation carriers are good candidates for chemoprevention. Furthermore, evidence increases indicating that the response of MMR-deficient tumors to standard chemotherapy and radiotherapy differs from that of MMR-proficient tumors. Efforts should thus be directed at designing tailored strategies concerning both chemoprevention and medical cancer treatment for LS individuals. This review provides guidance for future studies in this field based on results from clinical and preclinical research. (C) 2010 Elsevier Ireland Ltd. All rights reserved.",

keywords = "Lynch syndrome, Mismatch repair, Microsatellite instability, Chemoprevention, Cancer treatment, DNA MISMATCH-REPAIR, III COLON-CANCER, ACTIVATED PROTEIN-KINASE, MICROSATELLITE-INSTABILITY, CELL-LINES, ADJUVANT CHEMOTHERAPY, IONIZING-RADIATION, DEFICIENT CELLS, RANDOMIZED-TRIAL, INSTITUTE WORKSHOP",

author = "Heijink, {Dianne M.} and {de Vries}, {Elisabeth G. E.} and Koornstra, {Jan J.} and Hospers, {Geke A. P.} and Hofstra, {Robert M. W.} and {van Vugt}, {Marcel A. T. M.} and {de Jong}, Steven and Kleibeuker, {Jan H.}",

year = "2011",

month = nov,

doi = "10.1016/j.critrevonc.2010.11.009",

language = "English",

volume = "80",

pages = "264--277",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "ELSEVIER SCIENCE INC",

number = "2",

}

TY - JOUR

T1 - Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome

AU - Heijink, Dianne M.

AU - de Vries, Elisabeth G. E.

AU - Koornstra, Jan J.

AU - Hospers, Geke A. P.

AU - Hofstra, Robert M. W.

AU - van Vugt, Marcel A. T. M.

AU - de Jong, Steven

AU - Kleibeuker, Jan H.

PY - 2011/11

Y1 - 2011/11

N2 - Lynch syndrome (LS) is caused by a germline mutation in one of the mismatch repair (MMR) genes. The resulting loss of MMR gene function induces a strong mutator phenotype and predisposition to colorectal cancer (CRC). LS mutation carriers undergo regular colonoscopic surveillance and have extensive colonic resection in case of cancer because of the chance of metachronous tumors. Given the high risk and early onset of CRC, LS mutation carriers are good candidates for chemoprevention. Furthermore, evidence increases indicating that the response of MMR-deficient tumors to standard chemotherapy and radiotherapy differs from that of MMR-proficient tumors. Efforts should thus be directed at designing tailored strategies concerning both chemoprevention and medical cancer treatment for LS individuals. This review provides guidance for future studies in this field based on results from clinical and preclinical research. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

AB - Lynch syndrome (LS) is caused by a germline mutation in one of the mismatch repair (MMR) genes. The resulting loss of MMR gene function induces a strong mutator phenotype and predisposition to colorectal cancer (CRC). LS mutation carriers undergo regular colonoscopic surveillance and have extensive colonic resection in case of cancer because of the chance of metachronous tumors. Given the high risk and early onset of CRC, LS mutation carriers are good candidates for chemoprevention. Furthermore, evidence increases indicating that the response of MMR-deficient tumors to standard chemotherapy and radiotherapy differs from that of MMR-proficient tumors. Efforts should thus be directed at designing tailored strategies concerning both chemoprevention and medical cancer treatment for LS individuals. This review provides guidance for future studies in this field based on results from clinical and preclinical research. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

KW - Lynch syndrome

KW - Mismatch repair

KW - Microsatellite instability

KW - Chemoprevention

KW - Cancer treatment

KW - DNA MISMATCH-REPAIR

KW - III COLON-CANCER

KW - ACTIVATED PROTEIN-KINASE

KW - MICROSATELLITE-INSTABILITY

KW - CELL-LINES

KW - ADJUVANT CHEMOTHERAPY

KW - IONIZING-RADIATION

KW - DEFICIENT CELLS

KW - RANDOMIZED-TRIAL

KW - INSTITUTE WORKSHOP

U2 - 10.1016/j.critrevonc.2010.11.009

DO - 10.1016/j.critrevonc.2010.11.009

M3 - Review article

SN - 1040-8428

VL - 80

SP - 264

EP - 277

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 2

ER -

Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this